Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study
- 25 June 2012
- journal article
- research article
- Published by Taylor & Francis Ltd in Scandinavian Journal of Urology and Nephrology
- Vol. 46 (5), 381-388
- https://doi.org/10.3109/00365599.2012.693131
Abstract
Objective. Left ventricular hypertrophy (LVH) is highly prevalent in chronic kidney disease (CKD) and a risk marker for cardiovascular mortality. It was hypothesized that vitamin D deficiency could play an important role in the pathogenesis of left ventricular hypertrophy and dysfunction in CKD. An open-labelled randomized study was performed comparing the effect of alfacalcidol versus no treatment in patients with CKD 4, secondary hyperparathyroidism and LVH. The primary endpoint was regression of LVH. Secondary endpoints were changes in left ventricular function. Material and methods. Twenty-four patients were screened. Of these, 14 had LVH according to the criteria used. Six were randomized to alfacalcidol and seven to no treatment. The patient follow-up was 6 months. Left ventricular mass and function were measured by echocardiography. Results. Parathyroid hormone decreased by 72% and –3% in the alfacalcidol-treated and non-treated groups, respectively (p < 0.05), while serum Ca2+ increased by 9% and –1.6%, respectively (p < 0.05), and serum phosphate was unchanged. The left ventricular mass index was unchanged, whereas fractional shortening (20% vs 2%, p < 0.005) and Tei index (36% vs 12%, p < 0.05) increased significantly. Systolic and diastolic blood pressure was unchanged. Conclusion. Short-term treatment with alfacalcidol did not induce regression of LVH; however, left ventricular function became hyperdynamic but less effective in patients with CKD. This could be problematic in the long term.Keywords
This publication has 30 references indexed in Scilit:
- Hypertension, left ventricular hypertrophy and chronic kidney diseaseHeart Failure Reviews, 2010
- The vitamin D system: a crosstalk between the heart and kidneyEuropean Journal of Heart Failure, 2010
- Cardiovascular Disease and CKD: Core Curriculum 2010American Journal of Kidney Diseases, 2010
- Association of Oral Calcitriol with Improved Survival in Nondialyzed CKDJournal of the American Society of Nephrology, 2008
- Association of Activated Vitamin D Treatment and Mortality in Chronic Kidney DiseaseArchives of Internal Medicine, 2008
- Heart extracellular matrix gene expression profile in the vitamin D receptor knockout miceThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney diseaseKidney International, 2007
- Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobinAmerican Journal of Kidney Diseases, 1999
- Cardiac Disease in Chronic Uremia: PathogenesisAdvances in Renal Replacement Therapy, 1997
- 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes.JCI Insight, 1996